Application of tegrel in acute ST-segment elevation myocardial infarction
替格瑞洛在急性ST段抬高心肌梗死中的应用

摘要

目的 探讨替格瑞洛在急性ST段抬高心肌梗死中的应用价值。方法 选择45例于2020年1月-2022年11月期间需要进行治疗的急性ST段抬高心肌梗死患者作为观察组，对其采用替格瑞洛治疗，选择同期到我院就诊的另外45例急性ST段抬高心肌梗死患者作为对照组，对其采用氯吡格雷治疗。结果 ①治疗前对比观察组和对照组hs-CRP以及cTnI进行对比并无统计学意义，治疗后观察组hs-CRP、以及cTnI水平明显改善，组间比较P＜0.05；②观察组以及对照组呼吸频率、心率、血氧饱和度、收缩压以及舒张压水平在治疗前进行对比P＞0.05；观察组和对照组生命体征在治疗后进行对比P＜0.05。结论 急性ST段抬高心肌梗死患者采用替格瑞洛可将患者治疗效果改善，降低心血管不良事件发生率。

Abstract

Objective: To explore the application value of tegritol in acute ST-segment elevation myocardial infarction.
Methods: 45 patients with acute ST-segment elevation myocardial infarction who need to be treated from January 2020 to November 2022 were selected as the observation group, and they were treated with tegrel, and another 45 patients with acute ST-segment elevation myocardial infarction who visited our hospital at the same time were selected as the control group, and they were treated with clopidogrel.
Results: ① Before treatment, there was no statistically significant difference between the observation group and the control group in hs-CRP and cTnI. After treatment, the levels of hs-CRP and cTnI in the observation group were significantly improved, P<0.05; ② The respiratory rate, heart rate, blood oxygen saturation, systolic blood pressure and diastolic blood pressure in the observation group and the control group were compared before treatment (P>0.05); The vital signs of the observation group and the control group were compared after treatment (P<0.05).
Conclusion  : In patients with acute ST-segment elevation myocardial infarction, the treatment effect can be improved and the incidence of cardiovascular adverse events can be reduced.